Todas as categorias
| Product Name | Descrição | Action |
|---|---|---|
| Amivantamab,Rybrevant,EGFR, cMet (MET), JNJ-61186372, EGFR/c-MET anticorpo bispecífico, Completamente humano IgG1 bispecífico, Oncologia imunoterapia / NSCLC biológica, CAS n.o 2171511-58-1 | Trade Name : Rybrevant Target : EGFR, cMet (MET) Molecular Type : Bispecific Antibody Sales in 2025 (Millions of USD) : 179(First half of the year) All detailed product information shall be subject to the issued final COA. Should you need further in-depth documentation for this item, kindly get in ... |
|
| Polatuzumab vedotina, Polivy, CD79B, RG7596, ADC, terapia direcionada a CD79b, inibidor de microtúbulos, ADC oncológico / ADC de DLBCL / ADC de linfoma, infusão intravenosa, Nº CAS 1313206-42-6 | Trade Name : Polivy Target : CD79B Molecular Type : ADC Sales in 2025 (Millions of USD) : 850(First half of the year) All detailed product information shall be subject to the issued final COA. Should you need further in-depth documentation for this item, kindly get in touch with us. |
|
| Obinutuzumab | Trade Name : Gazyva Target : CD20 Molecular Type : Monoclonal Antibody Sales in 2025 (Millions of USD) : 784(First three quarters) All detailed product information shall be subject to the issued final COA. Should you need further in-depth documentation for this item, kindly get in touch with us. |
|
| Ivonescimabe, YIDAFANG® (nomes comerciais aprovados para uso na China), AK112, anticorpo biespecífico PD-1/VEGF, Imunoterapia oncológica / Terapia antiangiogênica, Anticorpo biespecífico PD-1/VEGF, Nº CAS.2428381-53-5 | Trade Name : YIDAFANG® (Trade names approved for use in China) Target : N/A Molecular Type : PD-1/VEGF Bispecific antibody Sales in 2025 (Millions of USD) : 28(In 2024) All detailed product information shall be subject to the issued final COA. Should you need further in-depth documentation for this ... |
|
| Datopotamab deruxtecan-dlnk,Datroway,TROP-2,DS-1062,ADC,TROP2 terapia direcionada,inibidor da topoisomerase I,ADC oncologia / NSCLC ADC / ADC cancro da mama, CAS n.o 2238831-60-0 | Trade Name : Datroway Target : TROP-2 Molecular Type : ADC Sales in 2025 (Millions of USD) : 10(First Quarter) All detailed product information shall be subject to the issued final COA. Should you need further in-depth documentation for this item, kindly get in touch with us. |
|
| Tenecteplase | Trade Name : Metalyse Target : Fibrin Molecular Type : Recombinant Protein Sales in 2025 (Millions of USD) : 1780(estimate) All detailed product information shall be subject to the issued final COA. Should you need further in-depth documentation for this item, kindly get in touch with us. |
|
| Tarlatamab, Imdelltra, DLL3&CD3, AMG 757, Imunoterapia oncológica / biológico de SCLC, Infusão intravenosa, Citotoxicidade mediada por células T, Engajador bispecífico de células T, Nº CAS.2307488-83-9 | Trade Name : Imdelltra Target : DLL3&CD3 Molecular Type : Bispecific T-cell Engager Sales in 2025 (Millions of USD) : 215(First half of the year) All detailed product information shall be subject to the issued final COA. Should you need further in-depth documentation for this item, kindly get in ... |
|
| Serplulimab,HANSIZHUANG,PD-1,Hetronifly,HLX10,Inhibitor do ponto de controlo imunitário anti-PD-1,Anticorpo monoclonal IgG4 humanizado,Anticorpo monoclonal,CAS n.o 2231029-82-4 | Trade Name : HANSIZHUANG Target : PD-1 Molecular Type : Monoclonal Antibody Sales in 2025 (Millions of USD) : 82(First half of the year) All detailed product information shall be subject to the issued final COA. Should you need further in-depth documentation for this item, kindly get in touch with ... |
